Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 7/20 | 0.61 |
| ▸ | KDR | P35968 | 6/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.44 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12663582 | 0.90 | PDGFRA (0.60) | PDGFRAKDRHTTMETPDGFRB | |
| SCHEMBL12663584 | 0.87 | PDGFRA (0.54) | PDGFRAKDRHTTMETPDGFRB | |
| SCHEMBL12663356 | 0.87 | PDGFRA (0.54) | PDGFRAKDRHTTMETPDGFRB | |
| SCHEMBL12663583 | 0.86 | PDGFRA (0.56) | PDGFRAKDRHTTMETPDGFRB | |
| SCHEMBL558651 | 0.86 | PDGFRA (0.80) | PDGFRAKDRMETPDGFRBFGFR2 | |
| SCHEMBL12663553 | 0.84 | KDR (0.59) | PDGFRAKDRMETFGFR2 | |
| SCHEMBL12663558 | 0.84 | PDGFRA (0.56) | PDGFRAKDRHTTMETFGFR2 | |
| SCHEMBL15537365 | 0.83 | KDR (0.63) | PDGFRAKDRMETPDGFRBFGFR2 | |
| SCHEMBL20022397 | 0.83 | HSPB1 (0.47) | PDGFRAKDRMETFGFR2HSPB1 | |
| SCHEMBL16089916 | 0.83 | PDGFRA (0.44) | PDGFRAKDRHTTPDGFRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243165-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-12275706-B2 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250084037-A1 | MALATE SALT OF N-(4-{[6,7-BIS(METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER | PHARMORPHIX (GB) | 2025-03-13 | — | — | US | disclosed |
| US-20240316030-A1 | METHOD OF TREATING CANCER AND BONE CANCER PAIN | EXELIXIS INC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240279181-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS INC (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240156803-A1 | Method of Treating Cancer | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-05-16 | — | — | US | disclosed |
| US-11969419-B2 | Method of treating cancer | EXELIXIS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20230314440-A1 | METHOD OF TREATING CANCER | EXELIXIS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230301980-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230181559-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. | 2023-06-15 | — | — | US | disclosed |
| EP-2461810-A1 | METHODS OF USING C-MET MODULATORS | Exelixis, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| WO-2012044572-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION- RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044577-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120070368-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| CN-102388024-A | Malate salt of N- (4- { [6, 7-bis (methyloxy) quinolin-4-yl ] oxy } phenyl) -N' - (4-fluorophenyl) cyclopropane-1, 1-dicarboxamide and crystalline form thereof for cancer treatment | EXELIXIS INC | 2012-03-21 | — | — | CN | disclosed |
| US-20120035212-A1 | (L)-Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| EP-2387563-A1 | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms therof for the treatment of cancer | Exelixis, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110252754-A1 | HORSEBACK RIDING SPUR MECHANISM | COOK KARL | 2011-10-20 | — | — | US | disclosed |
| US-20110118470-A1 | NITROGEN-CONTAINING AROMATIC DERIVATIVES | FUNAHASHI YASUHIRO | 2011-05-19 | — | — | US | disclosed |
| WO-2010083414-A1 | MALATE SALT OF N- (4- { [ 6, 7-BIS (METHYLOXY) QUIN0LIN-4-YL] OXY}PHENYL-N' - (4 -FLUOROPHENYL) CYCLOPROPANE-1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEROF FOR THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11969419-B2 | Method of treating cancer | MET, HGF, ACP3 | PDGFRA 109/4885KDR 8/4885HTT 4364/4885 |
| US-20240156803-A1 | Method of Treating Cancer | MET, HGF, ACP3 | PDGFRA 109/4885KDR 8/4885HTT 4364/4885 |
| US-20250243165-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, ME1 | PDGFRA 2690/4885KDR 4344/4885HTT 3890/4885 |
| US-20240316030-A1 | METHOD OF TREATING CANCER AND BONE CANCER PAIN | TPO, OGFR, CALCR | PDGFRA 2352/4885KDR 2332/4885HTT 3600/4885 |
| US-20230301980-A1 | Method of Treating Cancer | MET, HGF, ACP3 | PDGFRA 109/4885KDR 8/4885HTT 4364/4885 |
| US-20110118470-A1 | NITROGEN-CONTAINING AROMATIC DERIVATIVES | GNG2, GCG, FRG1 | PDGFRA 3135/4885KDR 2782/4885HTT 721/4885 |
| US-20240279181-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, ME1 | PDGFRA 2690/4885KDR 4344/4885HTT 3890/4885 |
| US-20120035212-A1 | (L)-Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | MDH1, MDH2, SLC25A11 | PDGFRA 3086/4885KDR 4302/4885HTT 3808/4885 |
| US-20120070368-A1 | Methods of Using C-Met Modulators | MET, KRAS, HGF | PDGFRA 112/4885KDR 603/4885HTT 3579/4885 |
| US-12275706-B2 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, SLC25A11 | PDGFRA 3001/4885KDR 4270/4885HTT 3372/4885 |
| US-20230181559-A1 | Methods of Using C-Met Modulators | MET, KRAS, HGF | PDGFRA 174/4885KDR 157/4885HTT 3310/4885 |
| US-20250084037-A1 | MALATE SALT OF N-(4-{[6,7-BIS(METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER | MDH1, MDH2, SLC25A11 | PDGFRA 3033/4885KDR 4284/4885HTT 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.